BHCHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Bausch Health Cos., Inc. hold a median 12-month price target of $7 — +8.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bausch Health Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (38): The shares have been drifting down relative to others.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +8.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Apr 2026 | RBC Capital | Maintains | Sector Perform | $10 → $9.00 |
| 25 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Jan 2026 | Truist Securities | Maintains | Hold | — |
| 9 Dec 2025 | Barclays | Initiates | Equal-Weight | — |
| 2 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 6 Feb 2025 | Jefferies | Downgrade | Hold | — |
| 30 Jan 2025 | RBC Capital | Maintains | Sector Perform | — |
| 1 Nov 2024 | RBC Capital | Maintains | Sector Perform | — |
| 2 Aug 2024 | Piper Sandler | Downgrade | Underweight | — |
| 2 Aug 2024 | RBC Capital | Maintains | Sector Perform | — |
| 25 July 2024 | Truist Securities | Maintains | Hold | — |
| 10 July 2024 | Raymond James | Initiates | Market Perform | — |
| 23 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 12 Apr 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 5 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 23 Feb 2024 | RBC Capital | Maintains | Sector Perform | — |
| 20 Sept 2023 | Jefferies | Upgrade | Buy | — |
| 16 June 2023 | TD Cowen | Downgrade | Market Perform | — |
| 22 May 2023 | Jefferies | Maintains | Buy | — |
| 5 May 2023 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 92% of US stocks
Cheaper than 96% of US stocks
Cheaper than 52% of US stocks
Higher than 58% of US stocks
Higher than 81% of US stocks
Higher than 85% of US stocks
Higher than 85% of US stocks
Higher than 20% of US stocks
Higher than 91% of US stocks
Higher than 83% of US stocks
Higher than 98% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bausch Health Cos., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Bausch Health shares have begun gaining and may continue moving higher in the near term, based on solid earnings estimate revisions.
Why it matters — A BHC watcher would care because rising earnings estimate revisions can signal improving expectations for the company's near-term performance.
Zacks Investment Research upgraded Bausch Health (BHC) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects, which could drive the stock higher in the near term.
Why it matters — A BHC watcher would care because the upgrade reflects improved expectations for the company's earnings outlook.
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, with Q2 2026 results showing 9% year-over-year revenue growth, margin expansion, and strong operating cash flow. Premium intraocular lenses and branded pharmaceuticals are driving faster growth and improving product mix, enabling margin and EBITDA expansion.
Why it matters — A BHC watcher would care because Bausch + Lomb's strong growth, margin expansion, and deleveraging prospects reflect positively on the broader Bausch Health performance and balance-sheet outlook.
Bausch Health Companies and its gastroenterology business Salix Pharmaceuticals announced the recipients of the 2026 Salix Gastrointestinal Health Scholars Program. For the seventh consecutive year, 10 students living with a gastrointestinal disease will each receive a $10,000 scholarship to support their higher education.
Why it matters — This highlights Bausch Health's ongoing community and patient-focused engagement within its GI business segment, supporting its corporate reputation and relationship with patients.
Bausch Health reported a Q2 non-GAAP EPS beat of $1.26 with 13% revenue growth and raised FY2026 guidance, sending shares up 40%. However, the company still faces significant balance sheet risks due to $15 billion in long-term debt and $800 million in first-half interest expenses.
Why it matters — Despite strong operational results and guidance, BHC watchers remain focused on the substantial debt overhang and low credit ratings that continue to weigh on the stock's outlook.
The 7 Wall Street analysts covering Bausch Health Cos., Inc. have a median 12-month price target of $7, with estimates ranging from $6.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Bausch Health Cos., Inc., 0 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bausch Health Cos., Inc. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Bausch Health Cos., Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +8.7% from the last close, and Ticker Nerd's factor model ranks Bausch Health Cos., Inc. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bausch Health Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $9 over the next 12 months.
Bausch Health Cos., Inc. returned -14.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Can Bausch (BHC) Run Higher on Rising Earnings Estimates?". Zacks reports that Bausch Health shares have begun gaining and may continue moving higher in the near term, based on solid earnings estimate revisions.
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.
CEO Mr. Thomas J. Appio · 20,300 employees · Canada · https://www.bauschhealth.com